NCT06982547

Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection

Clinical Study on the Treatment of Refractory Moderate - to - Severe Active Rheumatoid Arthritis With UTAA91 Injection

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.

Conditions

• Rheumatoid Arthritis (RA)

Interventions

Type	Name	Description
BIOLOGICAL	UTAA91 injection	After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.

Timeline

• Start date: 2025-06-01
• Primary completion: 2027-12-01
• Completion: 2040-06-01
• First posted: 2025-05-21
• Last updated: 2025-05-21

Locations

1 site across 1 country: China